

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

- 1. (currently amended)** A spiro-piperidine compound represented by formula (I):



wherein R¹ represents hydrogen, an aliphatic hydrocarbon group which may have a substituent(s) or a cyclic group which may have a substituent(s); and


ring A represents a ~~5- to 8-membered cyclic~~ tetrahydropyrimidin-2-(1H)-one group which may have a substituent(s), in which 2,5-diketopiperazine having a spiro bond at the 3-position is excluded, ~~ring A may be further condensed with ring B, and ring B represents a 3- to 8-membered monocyclic carbon ring or hetero ring which may have a substituent(s),~~

a salt thereof, an N-oxide thereof, a quaternary ammonium salt thereof or a solvate thereof, or a prodrug thereof, provided that 9-benzyl-1,3-dimethyl-1,3,9-triazospiro[5.5]undecan-2-one; 1,3-dimethyl-1,3,9-triazaspiro[5.5]undecan-2-one; 9-benzyl-1-methyl-1,3,9-triazospiro[5.5]undecan-2-one; and 1-methyl-1,3,9-triazaspiro[5.5]undecan-2-one are excluded.


2. (canceled).

3. (canceled).

4. (currently amended) The spiro-piperidine compound according to claim ~~3~~1, wherein the ring A is represented by




wherein ~~[[----]]~~ represents a single bond or a double bond; and
 R²[[, R³, R⁴]] and R⁵ each independently represents hydrogen, an aliphatic hydrocarbon group which may have a substituent(s), hydroxyl which may be protected, carboxy which may be protected, carbamoyl which may be protected, or a cyclic group which may have a substituent(s), ~~or R³ and R⁴ are taken together to represent~~



~~wherein Q¹ and Q² each independently represents hydrogen, an aliphatic hydrocarbon group which may have a substituent(s), hydroxyl which may be protected, carboxy which may be protected, carbamoyl which may be protected, or a cyclic group which may have a substituent(s); and~~

~~ring B represents a 3- to 8-membered monocyclic carbon ring or hetero ring which may have a substituent(s), and~~

~~wherein when ring A represents~~



~~R⁴ is present so long as [] represents a single bond,~~

~~a salt thereof, an N-oxide thereof, a quaternary ammonium salt thereof or a solvate thereof, or a prodrug thereof.~~

5. (canceled).

6. (canceled).

7. (Original): The spiro-piperidine compound according to claim 1, wherein R¹ is a C1-10 aliphatic hydrocarbon group which may have a substituent(s), a salt thereof, an N-oxide thereof, a quaternary ammonium salt thereof or a solvate thereof, or a prodrug thereof.

8. (original): The spiro-piperidine compound according to claim 1, wherein R¹ is a 5- to 10-membered monocyclic or bicyclic cyclic group which may have a substituent(s), a salt thereof, an N-oxide thereof, a quaternary ammonium salt thereof or a solvate thereof, or a prodrug thereof.

9. (currently amended): The spiro-piperidine compound according to claim 1, wherein R¹ is alkyl having from 1 to 6 carbon atoms ~~substituted~~substituted with a 3- to 10-membered monocyclic or bicyclic cyclic group which may have a substituent(s), a salt thereof, an N-oxide thereof, a quaternary ammonium salt thereof or a solvate thereof, or a prodrug thereof.

10. (withdrawn) A pharmaceutical composition which comprises the spiro-piperidine compound according to claim 1, a salt thereof, an N-oxide thereof, a quaternary ammonium salt thereof or a solvate thereof, or a prodrug thereof, and a pharmaceutically acceptable carrier or diluent.

11. (canceled).

12. (canceled).

13. (canceled).

14. (canceled).

15. (canceled).

16. (canceled).

17. (canceled).

18. (canceled).

19. (withdrawn-currently amended) A method for ~~preventing and/or treating~~ diseases ~~caused by CCR5 or CCR2 in a mammal~~selected from the group consisting of asthma, nepohritis, nephropathy, hepatitis, arthritis, rheumatoid arthritis, rhinitis, conjunctivitis, ulcerative colitis, rejection in organ transplantation, immunosuppression, psoriasis, multiple sclerosis, infection with human immunodeficiency virus , atopic dermatitis, uticaria, allergic bronchopulmonary aspergillosis, allergic eosinophilic gastroenteritis, ischemic reperfusion injury, acute respiratory distress syndrome, shock accompanying bacterial infection, diabetes mellitus, cancer metastasis and arteriosclerosis, which comprises administering to a mammal an effective amount of the spiro-piperidine compound according to claim 1, a salt thereof, an N-oxide thereof, a quaternary ammonium salt thereof or a solvate thereof, or a prodrug thereof.

20. (canceled).

21. (new): The spiro-piperidine compound according to claim 4, wherein R² is an aliphatic hydrocarbon group which may have a substituent(s) in which the aliphatic hydrocarbon group is selected from the group consisting of ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl, heptyl, octyl, C2-8 alkenyl and C2-8 alkynyl.